Pasithea Therapeutics CORP

Pasithea Therapeutics Corp. announced the appointment of Dr. Kartik Krishnan as Chief Medical Officer, effective May 1, 2026, to lead clinical development for PAS-004.

Pasithea Therapeutics Corp. stockholders approved significant increases in authorized common stock and shares available under its 2023 Stock Incentive Plan.

Pasithea Therapeutics Corp. announced it has regained compliance with Nasdaq's minimum bid price requirement, resolving a previous non-compliance issue.

Pasithea Therapeutics Corp. successfully closed a $60 million public offering, extending its cash runway through at least the first half of 2028.

Pasithea Therapeutics announced positive Phase 1 clinical trial data for its drug candidate PAS-004 across advanced cancer and NF1, alongside a $1 million grant from the ALS Association to study PAS-004 for ALS treatment.

Pasithea Therapeutics announced the activation of a new U.S. clinical trial site at the University of Alabama at Birmingham for its Phase 1/1b study of PAS-004 in adult NF1 patients.

Pasithea Therapeutics reports a net loss of $2.9 million for Q1 2026 as it continues clinical development of its lead candidate, PAS-004.

Pasithea Therapeutics reports continued clinical trial advancements for PAS-004 but faces significant operating losses and a going concern warning, necessitating further capital raises.

Pasithea Therapeutics reported a reduced net loss for Q2 2025, driven by clinical trial advancements for PAS-004 and successful capital raises, but faces ongoing liquidity concerns and a Nasdaq minimum bid price deficiency.

Pasithea Therapeutics reports a net loss of $3.56 million for Q1 2025 and provides an update on its clinical development programs and recent financing activities.

Pasithea Therapeutics reported a net loss of $2.99 million for the third quarter of 2024, while also providing updates on their clinical trial for PAS-004 and a recent capital raise.

Pasithea Therapeutics reported its Q2 2024 financial results, highlighting a net loss but also progress in its PAS-004 clinical trial.

Pasithea Therapeutics' 2024 annual report details financial results and provides updates on the clinical development of PAS-004 and other pipeline programs.

Pasithea Therapeutics Corp. released its 2023 annual report, detailing its shift to a therapeutics-focused company and progress in its clinical pipeline, particularly with PAS-004.

Pasithea Therapeutics Corp. reports the grant of stock options to CEO Tiago Marques, with specific vesting conditions and a 10-year expiration.

Pasithea Therapeutics Corp. reports that Director Lawrence Steinman was granted stock options exercisable at $0.84, vesting in full on May 1, 2026, or upon a Change in Control.

Pasithea Therapeutics Corp. reports that Director Simon Dumesnil was granted stock options under the company's 2023 Stock Incentive Plan.

Daniel H. Schneiderman, Chief Financial Officer of Pasithea Therapeutics Corp., was granted stock options under the company's 2023 Stock Incentive Plan.

Kartik Krishnan, Chief Medical Officer of Pasithea Therapeutics Corp., received a stock option grant for 1,129,323 shares.

Pasithea Therapeutics Corp. reports a Form 4 filing detailing the grant of stock options to Director Emer Leahy.

Pasithea Therapeutics Corp. is calling a Special Meeting of Stockholders to vote on increasing authorized common stock by 400% and expanding its 2023 Stock Incentive Plan.

Pasithea Therapeutics Corp. will hold its Annual Meeting of Stockholders to vote on key proposals including a reverse stock split to address Nasdaq's minimum bid price requirement and an increase in authorized shares for its equity incentive plan.

Pasithea Therapeutics will hold its annual stockholder meeting virtually on June 26, 2024, to vote on the election of a director and the ratification of its independent auditor.

Pasithea Therapeutics Corp. announced a public offering of up to $60 million in common stock and pre-funded warrants to fund its clinical-stage biotechnology programs, despite ongoing operating losses and Nasdaq compliance challenges.

Pasithea Therapeutics Corp. is offering up to $20.875 million in common stock, pre-funded warrants, and common warrants to fund operations and clinical trials, while facing Nasdaq delisting risk.

Pasithea Therapeutics launches a public offering of common stock and warrants, aiming to raise approximately $15.4 million to advance its pipeline of treatments for central nervous system disorders and other diseases.

Lawrence Steinman, Executive Chairman of Pasithea Therapeutics Corp., has filed an amended Schedule 13D indicating his beneficial ownership has fallen below the 5% threshold as of March 1, 2025.

Opaleye Management Inc., Opaleye L.P., and James Silverman have jointly filed a Schedule 13G, reporting beneficial ownership of 2,050,000 shares of Pasithea Therapeutics Corp. common stock, representing 6.14% of the outstanding shares.

Coastlands Capital LP and affiliated entities have reported beneficial ownership of 11.48% of Pasithea Therapeutics Corp.'s common stock as of April 9, 2026.

Ameriprise Financial, Inc. and its subsidiary Columbia Management Investment Advisers, LLC have filed a Schedule 13G, reporting beneficial ownership of 5.4% of Pasithea Therapeutics Corp. common stock as of March 31, 2026.

Funicular Funds, LP, along with affiliated entities Cable Car Capital, LP and Jacob Ma-Weaver, has disclosed beneficial ownership of 1,839,512 shares, representing 7.4% of Pasithea Therapeutics Corp.'s common stock.

Opaleye Management Inc. and James Silverman have disclosed a significant passive investment in Pasithea Therapeutics Corp., acquiring nearly 10% of the company.

Coastlands Capital LP and its affiliates have disclosed a 9.99% beneficial ownership stake in Pasithea Therapeutics Corp., comprising common stock and pre-funded warrants.